Notes from the Field: The National Wastewater Surveillance System's Centers of Excellence Contributions to Public Health Action During the Respiratory Virus Season - Four U.S. Jurisdictions, 2022-23.
Diana Valencia et al. MMWR Morb Mortal Wkly Rep 2023 11 (48) 1309-1312
From the article: "NWSS Centers of Excellence have reported correlation between WWS data and clinical surveillance with WWS allowing localized, timely coverage, and in some situations, valuable lead time notification. In Wisconsin, WWS detected increases in influenza and RSV weeks before increases in related emergency department visits were observed. NWSS data, together with clinical surveillance data, have guided jurisdictional partner decisions regarding allocation of resources, deployment of vaccination clinics, updating clinical guidance, and sending respiratory disease notifications and alerts when trends exceed baseline thresholds. During the 2022–23 respiratory disease season, NWSS Centers of Excellence translated WWS data into real-time public health action for multiple respiratory pathogens, highlighting the contribution of WWS in monitoring disease circulation and helping guide public health response. "
Evolutionary implications of SARS-CoV-2 vaccination for the future design of vaccination strategies.
Igor M Rouzine et al. Commun Med (Lond) 2023 6 (1) 86
Once the first SARS-CoV-2 vaccine became available, mass vaccination was the main pillar of the public health response to the COVID-19 pandemic. It was very effective in reducing hospitalizations and deaths. Here, we discuss the possibility that mass vaccination might accelerate SARS-CoV-2 evolution in antibody-binding regions compared to natural infection at the population level. Using the evidence of strong genetic variation in antibody-binding regions and taking advantage of the similarity between the envelope proteins of SARS-CoV-2 and influenza, we assume that immune selection pressure acting on these regions of the two viruses is similar.
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
Ivan T Lee et al. Nat Commun 2023 6 (1) 3631
Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent messenger RNA (mRNA) vaccine against seasonal influenza, mRNA-1010, from the first 2 parts of a 3-part, first-in-human, phase 1/2 clinical trial in healthy adults aged =18 years.
BA.1 Bivalent COVID-19 Vaccine Use and Stroke in England.
Nick Andrews et al. JAMA 2023 6
This analysis showed no evidence of an increased risk of stroke in the 21 days immediately after vaccination with either of the 2 mRNA COVID-19 bivalent BA.1 vaccines in England, with similar results for ischemic and hemorrhagic stroke and for the subset aged 65 years and older given influenza vaccine on the same day as the bivalent COVID-19 vaccine. For ischemic stroke, the upper bounds of CIs for the RI were all below the point estimate of a relative risk of 1.47.